Month: June 2021

Award recognizes SAFR’s collaboration on key projects, high quality of their solutions, and close alignment with Axis’ business practices and beliefsSAFR from RealNetworks, Inc. (NASDAQ: RNWK) ), a leader in high accuracy, low bias facial recognition.Seattle, WA, June 27, 2021 (GLOBE NEWSWIRE) — SAFR from RealNetworks, Inc. (NASDAQ: RNWK) ), a leader in high accuracy, low bias facial recognition, is pleased to announce that Axis Communications, a global leader in network video and surveillance products, has chosen SAFR as Best Ecosystem Partner 2020 for both the Middle East, and for Africa. The awards were presented during the Axis Annual Partner Awards in a virtual ceremony held on 23 June 2021, as part of Axis Innovates event. The awards celebrated and acknowledged the efforts of Axis’ partners by recognizing...

Bagsværd, Denmark, 26 June 2021 – Novo Nordisk today presented data showing that an investigational 2.0 mg dose of Ozempic® (semaglutide) provided statistically significant and superior reductions in blood sugar (HbA1C) compared with Ozempic® 1.0 mg1. These data were the outcome of the SUSTAIN FORTE trial, a phase 3b, 40-week, efficacy and safety trial comparing once-weekly semaglutide 2.0 mg vs Ozempic® 1.0 mg as add-on to metformin with or without sulfonylureas in 961 adults with type 2 diabetes in need of additional blood sugar reduction. The results were presented at the 81st Annual Scientific Sessions of the American Diabetes Association (ADA)1,2 and primary results are in press for publication in The Lancet Diabetes & Endocrinology. The trial met its primary endpoint, where people treated with once-weekly semaglutide 2.0 mg...

Intellia Therapeutics LogoIntellia Therapeutics LogoJohn Leonard, M.D., President and CEO, Intellia TherapeuticsJohn Leonard, M.D., President and CEO, Intellia TherapeuticsAbout Transthyretin (ATTR) AmyloidosisAbout Transthyretin (ATTR) AmyloidosisHow NTLA-2001 WorksHow NTLA-2001 WorksRegeneron Pharmaceuticals LogoRegeneron Pharmaceuticals LogoFirst-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean reduction in serum TTR, with a maximum 96% serum TTR reduction by day 28, with dose-dependent response Encouraging safety profile; no serious adverse events observed in the first six patients by day 28 Data published...

First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression Transplanting allogeneic cells into a primate without immune suppression represents a key step toward widespread treatment of disease using engineered cells SEATTLE, June 26, 2021 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today presented data showing survival of transplanted stem cells without immunosuppression in non-human primates (NHPs). The transplanted cells were induced pluripotent stem cells (iPSCs) with Sana’s hypoimmune gene modifications that enable immune evasion. Data were presented by Sonja Schrepfer, M.D., Ph.D., Head of Hypoimmune Platform at Sana, during the plenary...

AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks AB-729 resulted in HBsAg declines below 100 IU/ml in 75% of treated subjects, and increased HBV-specific immune responses in 3/5 evaluable subjects AB-729 resulted in decreases in HBV RNA and all HBsAg isoforms demonstrating broad target engagement AB-729 dosed for 48 weeks continued to demonstrate a favorable safety and tolerability profile AB-836 pre-clinical data suggest the potential for increased efficacy and an enhanced resistance profile relative to previous generation capsid inhibitors Conference Call and Webcast Scheduled for 8:00 AM ET, Monday, June 28th, 2021 WARMINSTER, Pa., June 26, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical...

VANCOUVER, British Columbia, June 25, 2021 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company”) (TSX:III) is pleased to announce the successful completion of its previously announced rights offering (the “Rights Offering”), which expired at 2:00 p.m. (Pacific Time) today. The Company will issue a total of 12,853,267 common shares in the Rights Offering for gross proceeds of approximately $60.4 million. The Company will issue a total of 10,992,281 common shares under basic subscription privileges in the Rights Offering and a total of 1,860,986 common shares under additional subscription privileges. To the knowledge of the Company, no person will become an insider as a result of the Rights Offering. The total number of issued and outstanding common shares of the Company upon completion of the Rights Offering will be 141,392,191. The...

BRIDGEWATER, N.J., June 25, 2021 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (SNCR) (the “Company” or “Synchronoss”), a global leader and innovator in cloud, messaging and digital products and platforms, today announced the pricing of an underwritten public offering of $125 million aggregate principal amount of 8.375% senior notes due 2026, including the exercise in full by the underwriters of the underwriters’ option to purchase an additional $5 million aggregate principal amount of senior notes. The offering is expected to close on or about June 30, 2021, subject to satisfaction of customary closing conditions. Synchronoss and the senior notes both received a rating of BB- from Egan-Jones Ratings Company, an independent, unaffiliated rating agency. The Company has applied to list the senior notes on the Nasdaq Global Select...

TORONTO, June 25, 2021 (GLOBE NEWSWIRE) — In accordance with regulatory requirements, Dundee Corporation (TSX: DC.A) announces that its wholly owned subsidiary, Goodman & Company, Investment Counsel Inc. on behalf of managed accounts, has disposed of 2,000,000 common shares (“Shares”) of Cantex Mine Development Corp. (TSXV:CD) (the “Issuer”) at an average price of $0.51 per share. Immediately prior to the disposition of securities described in this news release, Dundee owned or controlled 4,214,545 Shares and warrants to purchase up to 2,000,000 Shares representing an approximate 7.92% interest in the Issuer on an undiluted basis and 11.25% on a partially diluted basis. Immediately following the transaction that triggered the requirement to file this news release, Dundee owns 2,214,545 Shares and warrants to purchase up to...